Evidence map›Paper›PMID 24719317›Full record

ArticleThe Journal of biological chemistry2014

Neurolysin knockout mice generation and initial phenotype characterization.

Diogo M L P Cavalcanti, Leandro M Castro, José C Rosa Neto, Marilia Seelaender, Rodrigo X Neves, Vitor Oliveira, Fábio L Forti, Leo K Iwai, Fabio C Gozzo, Mihail Todiras and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Methods for Intracellular Peptidomic Analysis.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  3. Review
  4. Neurolysin Knockout Mice in a Diet-Induced Obesity Model.International journal of molecular sciences · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Targeting neurolysin in acute myeloid leukemia.Molecular & cellular oncology · 2020
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Diogo M L P CavalcantiFrom the Departments of Cell Biology and Development and.
Leandro M CastroPharmacology, Support Center for Research in Proteolysis and Cell Signaling, Biomedical Sciences Institute, University of São Paulo, São Paulo, SP 05508-900, Brazil, the Department of Biophysics, Federal University of São Paulo, São Paulo, SP 04039-032, Brazil.
José C Rosa NetoFrom the Departments of Cell Biology and Development and.
Marilia SeelaenderFrom the Departments of Cell Biology and Development and.
Rodrigo X NevesFrom the Departments of Cell Biology and Development and.
Vitor Oliveirathe Department of Biophysics, Federal University of São Paulo, São Paulo, SP 04039-032, Brazil.
Fábio L Fortithe Department of Biochemistry, Support Center for Research in Proteolysis and Cell Signaling, Institute of Chemistry, University of São Paulo, São Paulo, SP 05508-000, Brazil.
Leo K Iwaithe Special Laboratory of Applied Toxinology, Center of Toxins, Immune Response and Cell Signaling, Butantan Institute, São Paulo, SP 05503-000, Brazil.
Fabio C Gozzothe Institute of Chemistry, State University of Campinas, Campinas, SP 13083-862, Brazil.
Mihail Todirasthe Max-Delbrück-Center for Molecular Medicine, D-13125, Berlin, Germany, and.
Ines Schadockthe Max-Delbrück-Center for Molecular Medicine, D-13125, Berlin, Germany, and.
Carlos C Barrosthe Max-Delbrück-Center for Molecular Medicine, D-13125, Berlin, Germany, and the Department of Nutrition, Federal University of Pelotas, Pelotas, RS 96010-610, Brazil.
Michael Baderthe Max-Delbrück-Center for Molecular Medicine, D-13125, Berlin, Germany, and.
Emer S FerroPharmacology, Support Center for Research in Proteolysis and Cell Signaling, Biomedical Sciences Institute, University of São Paulo, São Paulo, SP 05508-900, Brazil, eferro@usp.br.
Universidade Federal de São Paulo · BRInstituto Butantan · BRUniversidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BRUniversidade Federal de Pelotas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oligopeptidase neurolysin (EC 3.4.24.16; Nln) was first identified in rat brain synaptic membranes and shown to ubiquitously participate in the catabolism of bioactive peptides such as neurotensin and bradykinin. Recently, it was suggested that Nln reduction could improve insulin sensitivity. Here, we have shown that Nln KO mice have increased glucose tolerance, insulin sensitivity, and gluconeogenesis. KO mice have increased liver mRNA for several genes related to gluconeogenesis. Isotopic label semiquantitative peptidomic analysis suggests an increase in specific intracellular peptides in gastrocnemius and epididymal adipose tissue, which likely is involved with the increased glucose tolerance and insulin sensitivity in the KO mice. These results suggest the exciting new possibility that Nln is a key enzyme for energy metabolism and could be a novel therapeutic target to improve glucose uptake and insulin sensitivity.

Indexed as

Adipose TissueAnimalsBlood GlucoseBlood PressureGenotypeGluconeogenesisGlucose IntoleranceInsulin ResistanceLiverMetalloendopeptidasesMiceMice, Inbred C57BLMice, KnockoutMuscle Fibers, Fast-TwitchMuscle, SkeletalPhenotypeBlood GlucoseMetalloendopeptidasesneurolysinPyruvic AcidGluconeogenesisGlucose MetabolismInsulinIntracellular PeptidesOligopeptidasePeptidasesPeptides

Identifiers

PMID24719317
PMCPMC4140899
OpenAlexW2012591661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.